Global Ovarian Cancer Drugs Market was valued at USD 2,511.11 Million and is projected to reach a market size of USD 11,128.94 Million by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 23.7%. with the United States leading the way. One of the primary trends driving market expansion is the rising incidence of ovarian cancer due to an ageing population and bad lifestyles.
MARKET OVERVIEW
Ovarian cancer is caused by the growth of mutational cells or tissues in the female reproductive organs known as the ovaries. Cancer goes undiagnosed until the mutation spreads to the stomach and pelvis, resulting in a deadly stage of ovarian cancer. Ovarian cancer claims the lives of a significant number of women around the world. Women with ovarian cancer may experience pain in the belly, exhaustion, indigestion, bloating, and nausea, among other symptoms.
Ovarian cancer is the seventh most frequent cancer in women globally, according to the World Malignancy Research Fund International (WCRF), and it kills more people each year than any other gynaecological cancer. This condition affects mostly older women, with a peak age of 63. Over the last decade, the global mortality rate has decreased, and this trend is expected to continue in the United States, Europe, and, to a lesser extent, Japan during the forecast period. The usage of contraceptives is on the rise, while hormonal therapies are on the decline, resulting in a lower cancer-related mortality rate.
PARP inhibitors are expected to account for the bulk of market share in 2022, owing to the sustained consumption of authorised medications and their higher efficacy. The market's growth is expected to be aided by the increasing use of checkpoint inhibitors.
COVID-19 impact on Ovarian Cancer Drugs Market
The pandemic of COVID-19 has had a negative influence on healthcare systems and the market. As the world grapples with the coronavirus sickness catastrophe of 2020, the oncology community faces unprecedented problems. During this challenging time, patients with ovarian cancer (OC) have experienced delays in diagnosis, surgery, chemotherapy, radiation therapy, and oncology follow-ups conducted via telemedicine rather than in-person appointments. COVID-19 and cancer treatment risks are weighed against the benefits of delaying cancer therapy by OC patients and their doctors. Due to the delay in treatment therapy, women with OC have reported greater levels of cancer fear, anxiety, and despair.
MARKET DRIVERS
The growing prevalence of ovarian cancer and the rise in the number of elderly women are both driving the global ovarian cancer market forward.
The rise of healthcare is being driven by the growing economies of both developed and developing countries. As a result, they are helping to drive the worldwide ovarian cancer market forward. The global ovarian cancer market is expected to grow in response to the growing geriatric population of women, the growth in ovarian cancer incidence, the ease of use of novel medicines and therapies, and rising healthcare spending. In addition, the market's rise is being aided by increased government funding.
Emerging Trends in Ovarian Cancer Treatment Driving the Market Growth.
As the female population has gotten older, ovarian cancer has become more common. Rising ovarian cancer prevalence, the introduction of new drugs and therapies, increased healthcare expenditure, and more government financing are some of the other major factors propelling the ovarian cancer market forward. Furthermore, the ovarian cancer industry is being propelled ahead by rising healthcare awareness. As a result, medications like Bevacizumab (Avastin) and Pazopanib (Votrient) are likely to grow in popularity, replacing generics like paclitaxel and carboplatin, which currently dominate the market. Furthermore, the discovery of new treatments to treat this type of cancer is projected to have a substantial impact on the market.
MARKET RESTRAINTS
The market's expansion is being stifled by a lack of awareness.
The symptoms of ovarian cancer are frequently overlooked and easily mistaken with those of other disorders, resulting in a lack of early detection and accurate diagnosis. The market for ovarian cancer diagnostics and therapies in Asia-Pacific is being hampered by this. Other organs affected by ovarian cancer include the abdominal cavity, pelvis, and abdominal lymph nodes, as well as the bones, liver, brain, and the sac around the lymph nodes. Furthermore, the worldwide market is being hindered by the expiration of key pharmaceutical patents. The market may face difficulty when it develops increasingly effective medications.
The market's expansion is being stifled by a lack of skilled professionals and technology.
Furthermore, the lack of suitable technology for identifying ovarian cancer in its early stages is a major issue impeding the worldwide ovarian cancer market's growth. Furthermore, the shortage of experienced individuals is posing a challenge to the market's growth. In addition, the ovarian cancer market's growth is being hampered by a shortage of funding for research and development operations.
OVARIAN CANCER DRUGS MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2023 - 2030 |
|
Base Year |
2023 |
|
Forecast Period |
2024 - 2030 |
|
CAGR |
23.7% |
|
Segments Covered |
By Class, Treatment, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
AstraZeneca, Roche, Tesaro, and Clovis Oncology, Pfizer, AbbVie, ImmunoGen, Johnson & Johnson, Boehringer Ingelheim, Oasmia Pharmaceuticals |
PARP
PD-L1
Angiogenesis Inhibitors
AstraZeneca was the only player in the PARP inhibitors market for two years. Rubraca from Clovis Oncology was authorised as a third-line therapy for indication in 2020. Tesaro's Zejula was approved by the FDA in March 2021 as a maintenance medication for individuals with BRCA mutations. Both Zejula and Rubraca, PARP inhibitors, have shown promising outcomes in early trials and compete directly with AstraZeneca's Lynparza.
The use of innovative treatments such as immunotherapy, targeted therapy, and, most significantly, combination regimens are the focus of current ovarian cancer research. Immuno-oncologic drugs have shown encouraging outcomes in terms of increased survival and reduced toxicity. However, the single-agent response rate of PD-1/PD-L1 drugs like Opdivo and Keytruda for the treatment of ovarian cancer is less than 20%.
Chemotherapy
Radiation Therapy
Hormonal Therapy
Surgery
Immunotherapy
Targeted Therapy
Immunotherapy dominates the market in terms of treatment type. It is expected to develop rapidly throughout the forecast period, owing to the rising adoption rate of immunotherapy treatments and the growth of healthcare, which has increased the number of patients diagnosed with ovarian cancer who are undergoing immunotherapy.
The market for targeted therapies is growing at a rapid rate of CAGR. Due to the increasing popularity of targeted therapies and the rising prevalence of women affected by ovarian cancer, this trend is expected to continue during the projection period.
North America
Europe
Asia-Pacific
Latin America
The Middle East and Africa
In terms of geography, North America held the largest proportion of the global ovarian cancer market in 2020. Due to the increasing prevalence of ovarian cancer and the growing geriatric population, the trend is expected to continue during the forecast period. The United States has the largest share of the ovarian cancer diagnostics and therapies market and has greatly increased its share. In the United States, ovarian cancer is the ninth most frequent cancer and the fifth greatest cause of cancer death among women. Furthermore, the United States is home to the majority of the world's top ovarian cancer diagnostics companies. As a result, it is likely to be a substantial advantage for the area, driving the market.
Demand from Asia-Pacific accounts for a considerable portion of the company's sales. . Due to the rising incidence of the elderly population and the growing economy of countries such as China and India, it is expected to rise at a high CAGR throughout the forecast period. Due to rising healthcare spending, more government assistance, and an expanding target patient pool, India and China are the fastest emerging countries in the Asia Pacific. According to the World Health Organization, more than 7 million new cancer cases are discovered in Asia each year (WHO). China and India are two of the most promising countries in the world, with significant market potential. Rising ovarian cancer incidence, favourable medical care reforms, improved health awareness, a low-cost base, and the absence of legal and cultural restrictions all contribute to the market's rise in India and other developing countries. As a result, the ovarian cancer diagnostics market in Asia-Pacific is rapidly expanding.
Ovarian Cancer Drugs Market - by company
AstraZeneca
Roche
Tesaro
Clovis Oncology
Pfizer
AbbVie
ImmunoGen
Johnson & Johnson
Boehringer Ingelheim
Oasmia Pharmaceuticals
Avastin's market share is expected to be impacted by patent expiration and increased competition from PARP inhibitors. In the second-line platinum-sensitive scenario, Roche's Tecentriq-based combination therapy is projected to gain traction as the preferred treatment option. For advanced-stage patients with BRCA mutations, PARP inhibitors are expected to become the recommended maintenance therapy. When compared to current standard-of-care chemotherapy, the medication class is expected to significantly enhance progression-free survival (PFS).
NOTABLE HAPPENINGS IN THE OVARIAN CANCER DRUGS Market IN RECENT PAST.
RESEARCH AND DEVELOPMENT:
In February 2021, GlaxoSmithKline plc has developed a new treatment for advanced ovarian cancer in women the FDA authorised a medicine named zejula, with the FDA aiming for a quick review procedure to make it available to patients.
In August 2020, Researchers from The George Washington University School of Medicine and Health Sciences in the United States discovered an ovarian cancer medication resistance protein that needs to be blocked for the treatment of platinum-resistant ovarian cancer patients.
MERGERS AND ACQUISITIONS:
In January 2020, Tesaro was purchased by GlaxoSmithKline (GSK), a UK-based pharmaceutical company, for $5.1 billion. With Tesaro's Zejula, a PARP inhibitor, and other Tesaro products, GSK will be able to grow its product portfolio and boost its pharmaceutical company by speeding the development of GSK's pipeline and commercial capacity in oncology.
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
